摘要
背景:阿尔茨海默症(AD)是痴呆的最常见形式。任何认知缺失的症状经过20年都可能发展成为AD。因此,早期诊断和保护系统的发展都非常重要。AD的机制现仍存在争论。然而,AD患者脑脊液和血浆中被检测到高水平的糖化白蛋白。因此,糖化白蛋白可能成为AD发展中的生物标记物。 途径:电化学生物传感器精确检测糖化白蛋白是基于由二乙烯三胺五乙酸(DTPA)的钴(II) 螯合物构成的金电极表面。组氨酸标记的晚期糖基化终末产物(RAGE)受体的区域被当作糖化白蛋白的活性分析元素。糖化白蛋白与组氨酸6-晚期糖基化终末产物的连接由奥斯特扬方波伏安法检测。 结果:通过组氨酸6-晚期糖基化终末产物VC1自然领域修饰的电极使糖化白蛋白钴(II) 的氧化还原反应减少。人体白蛋白,Aβ 1-40 和 S100B 蛋白对生物传感器回应糖化白蛋白的影响可忽略不计。在不同的缓冲液条件下,检测限分别为2.3pM(缓冲液),1.1pM(含白蛋白缓冲液),2.9pM(含S100B缓冲液),3.1pM(含Aβ1-40 缓冲液)。 结论:现在的电化学生物传感器已经成功应用于糖化白蛋白的检测。考虑到分析参数(如在pM级别的好的选择性和灵敏度),生物传感器可能成为一种药物样品分析的工具。
关键词: 阿尔茨海默症,喷替酸-钴螯合物,糖化白蛋白,组氨酸标记的晚期糖基化终末产物区域,电化学生物传感器,氧化还原活性单层,潜在AD生物标记物
Current Alzheimer Research
Title:Electrochemical Biosensor for the Detection of Glycated Albumin
Volume: 14 Issue: 3
关键词: 阿尔茨海默症,喷替酸-钴螯合物,糖化白蛋白,组氨酸标记的晚期糖基化终末产物区域,电化学生物传感器,氧化还原活性单层,潜在AD生物标记物
摘要: Background: Alzheimer’s disease (AD) is the most common form of dementia. The process of AD can begin 20 years before any symptom of cognitive loss. Thus, the development of systems for early diagnosis and prevention is very important. The mechanism of AD is still under debate. Nevertheless, higher levels of glycated albumin in cerebrospinal fluid and plasma are observed in AD patients. Therefore, glycated albumin could be a biomarker of AD development.
Methods: Electrochemical biosensor for direct determination of glycated albumin was based on thiol derivative of pentetic acid (DTPA) complex with Cu(II) created on gold electrode surface. His-tagged domains of Receptors for Advanced Glycation End Products (RAGE) were applied as analytical active element for glycated albumin recognition. The binding of glycated albumin by His6- RAGE domains was monitored using Osteryoung square - wave voltammetry. Results: Electrodes modified with His6 - RAGE VC1 natural domain generated decrease of Cu(II) redox currents in the presence of glycated albumin. Human albumin, Aβ 1-40 and S100B protein caused negligible influence on biosensors responses towards glycated albumin. The detection limits were: 2.3 pM, 1.1 pM, 2.9 pM and 3.1 pM in the presence of: buffer, buffer + albumin, buffer + S100B, buffer + Aβ1-40 , respectively. Conclusion: The presented electrochemical biosensor was successfully applied for the determination of glycated albumin. Considering analytical parameters such as good selectivity and sensitivity in pM range, biosensor could be recommended as an analytical tool for medical samples analysis.Export Options
About this article
Cite this article as:
Electrochemical Biosensor for the Detection of Glycated Albumin, Current Alzheimer Research 2017; 14 (3) . https://dx.doi.org/10.2174/1567205013666161108110542
DOI https://dx.doi.org/10.2174/1567205013666161108110542 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neuroprotective Actions of Flavones and Flavonols: Mechanisms and Relationship to Flavonoid Structural Features
Central Nervous System Agents in Medicinal Chemistry HIV-1, Methamphetamine and Astrocyte Glutamate Regulation: Combined Excitotoxic Implications for Neuro-AIDS
Current HIV Research The Putative Use of Lithium in Alzheimer’s Disease
Current Alzheimer Research Differential Expression of Ribosomal Genes in Brain and Blood of Alzheimer’s Disease Patients
Current Alzheimer Research Pathophysiology of Blood-Spinal Cord Barrier in Traumatic Injury and Repair
Current Pharmaceutical Design Pharmacologic Strategies for Suppression of Lipid Peroxidation in Neurodegeneration
Current Neuropharmacology Therapeutic Targets in the Ubiquitin-proteasome System for Alzheimer's Disease
Current Enzyme Inhibition Oxidative and Inflammatory Events in Prion Diseases: Can They Be Therapeutic Targets?
Current Aging Science The Links between Cardiovascular Diseases and Alzheimer's Disease
Current Neuropharmacology Blood Brain Barrier and Alzheimer’s Disease: Similarity and Dissimilarity of Molecular Alerts
Current Neuropharmacology Oxidative Damage, Protein Synthesis, and Protein Degradation in Alzheimers Disease
Current Alzheimer Research Review of Bioinformatics and Theoretical Studies of Acetylcholinesterase Inhibitors
Current Bioinformatics Recent Patent Advances for Neurodegenerative Disorders and its Treatment
Recent Patents on Drug Delivery & Formulation Current Updates in Transdermal Therapeutic Systems and Their Role in Neurological Disorders
Current Protein & Peptide Science Patient-Specific Modeling and Multi-Scale Blood Simulation for Computational Hemodynamic Study on the Human Cerebrovascular System
Current Pharmaceutical Biotechnology Advances in Drug Delivery from Nose to Brain: An Overview
Current Drug Therapy Apoptosis in Alzheimer Disease: A Mathematical Improbability
Current Alzheimer Research Nanotechnology and Alzheimer's Disease: What has been Done and What to Do'
Current Medicinal Chemistry The Role of P-glycoprotein in Cerebral Amyloid Angiopathy; Implications for the Early Pathogenesis of Alzheimers Disease
Current Alzheimer Research The Contribution of Proteinase-Activated Receptors to Intracellular Signaling, Transcellular Transport and Autophagy in Alzheimer´s Disease
Current Alzheimer Research